The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Open accessAbstract
BACKGROUND: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence. The analysis reported here, with an additional 6 months of follow-up, was designed to assess longer-term efficacy and safety of pembrolizumab versus placebo, as well as additional secondary and exploratory endpoints. METHODS: In the multicentre, randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-564 trial, adults aged 18 years or older with clear cell renal cell carcinoma with an increased risk of recurrence were enrolled at 213 hospitals and cancer centres in North America, South America, Europe, Asia, and Australia. Eligible participants had an Eastern Cooperative Oncology Group performance status of 0 or 1, had undergone nephrectomy 12 weeks or less before randomisation, and had not received previous systemic therapy for advanced renal cell carcinoma. Participants were randomly assigned (1:1) via central permuted block randomisation (block size of four) to receive pembrolizumab 200 mg or placebo intravenously every 3 weeks for up to 17 cycles. Randomisation was stratified by metastatic disease status (M0 vs M1), and the M0 group was further stratified by ECOG performance status and geographical region. All participants and investigators involved in study treatment administration were masked to the treatment group assignment. The primary endpoint was disease-free survival by investigator assessment in the intention-to-treat population (all participants randomly assigned to a treatment). Safety was assessed in the safety population, comprising all participants who received at least one dose of pembrolizumab or placebo. As the primary endpoint was met at the first interim analysis, updated data are reported without p values. This study is ongoing, but no longer recruiting, and is registered with ClinicalTrials.gov, NCT03142334. FINDINGS: Between June 30, 2017, and Sept 20, 2019, 994 participants were assigned to receive pembrolizumab (n=496) or placebo (n=498). Median follow-up, defined as the time from randomisation to data cutoff (June 14, 2021), was 30·1 months (IQR 25·7-36·7). Disease-free survival was better with pembrolizumab compared with placebo (HR 0·63 [95% CI 0·50-0·80]). Median disease-free survival was not reached in either group. The most common all-cause grade 3-4 adverse events were hypertension (in 14 [3%] of 496 participants) and increased alanine aminotransferase (in 11 [2%]) in the pembrolizumab group, and hypertension (in 13 [3%] of 498 participants) in the placebo group. Serious adverse events attributed to study treatment occurred in 59 (12%) participants in the pembrolizumab group and one (<1%) participant in the placebo group. No deaths were attributed to pembrolizumab. INTERPRETATION: Updated results from KEYNOTE-564 support the use of adjuvant pembrolizumab monotherapy as a standard of care for participants with renal cell carcinoma with an increased risk of recurrence after nephrectomy. FUNDING: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognostic significance of morphologic parameters in renal cell carcinoma
Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198210000-00007 · Cited by 2,724
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz056 · Cited by 1,151
Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., Weaver, A. L., Parker, A. S., & Zincke, H. (2003) · Cancer · doi:10.1002/cncr.11234 · Cited by 837
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y.-H., Hajek, J., Symeonides, S. N., Lee, J. L., Sarwar, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106391 · Cited by 785
Self-citationAdjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611406 · Cited by 782
Self-citationHaas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00559-6 · Cited by 630
Self-citationResection of metastatic renal cell carcinoma.
Kavolius, J. P., Mastorakos, D. P., Pavlovich, C., Russo, P., Burt, M. E., & Brady, M. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2261 · Cited by 559
Motzer, R. J., Haas, N. B., Donskov, F., Gross-Goupil, M., Varlamov, S., Kopyltsov, E., Lee, J. L., Melichar, B., Rini, B. I., Choueiri, T. K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.5324 · Cited by 382
Self-citation
Cited by
Renal Cell Carcinoma: A Review
Rose, T. L., & Kim, W. Y. (2024) · JAMA · doi:10.1001/jama.2024.12848 · Cited by 374
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y.-H., Lee, J.-L., Sarwar, N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312695 · Cited by 346
Self-citationEuropean Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
Bex, A., Ghanem, Y. A., Albiges, L., Bonn, S., Campi, R., Capitanio, U., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.02.020 · Cited by 345
Self-citationRaghubar, A. M., Matigian, N. A., Crawford, J., Francis, L., Ellis, R., Healy, H. G., Kassianos, A. J., Ng, M. S. Y., Roberts, M. J., Wood, S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00441-5 · Cited by 26
Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
Cosso, F., Roviello, G., Nesi, G., Shabani, S., Spatafora, P., Villari, D., & Catalano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044243 · Cited by 18
Metadata
- Authors
- Powles, T., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Gurney, H., Chang, Y.-H., Lee, J. L., Sarwar, N., Thiery-Vuillemin, A., Gross-Goupil, M., Mahave, M., Haas, N. B., Sawrycki, P., Burgents, J. E., Xu, L., Imai, K., Quinn, D. I., Choueiri, T. K., Tomczak, P., Choueiri, T., Park, S. H., Venugopal, B., Ferguson, T. R., Hajek, J., Lin, T.-P., Symeonides, S. N., Lee, J. L., Sawrycki, P., Haas, N. B., Gurney, H. P., Mahave, M., Sarwar, N., Thiery-Vuillemin, A., Gross-Goupil, M., Chevreau, C., Burke, J. M., Doshi, G., Melichar, B., Topart, D., Oudard, S., Kopyltsov, E., Hammers, H.-J., Quinn, D. I., Alva, A., Menezes, J. D. J., Silva, A. G. E., Winquist, E. W., Hamzaj, A., Procopio, G., Karaszewska, B., Nowakowska-Zajdel, E. M., Alekseev, B. Y., Gafanov, R. A., Izmailov, A., Semenov, A., Afanasyev, S. G., Lipatov, O. N., Powles, T. B., Srinivas, S., McDermott, D., Kochuparambil, S. T., Davis, I. D., Peltola, K., Sabbatini, R., Chung, J., Shkolnik, M. I., Matveev, V. B., Gajate Borau, P., McCune, S., Hutson, T. E., Dri, A., Sales, S. C., Yeung, C., Alcala Castro, C. M., Bostrom, P., Laguerre, B., Buttigliero, C., de Giorgi, U., Fomin, E. A., Zakharia, Y., Hwang, C., Singer, E. A., Yorio, J. T., Waterhouse, D., Kowalyszyn, R. D., Alfie, M. S., Yanez Ruiz, E., Buchler, T., Kankaanranta, K., Ferretti, G., Kimura, G., Nishimura, K., Masumori, N., Tamada, S., Kato, H., Kitamura, H., Danielewicz, I., Wojcik-Tomaszewska, J., Sala Gonzalez, N., Chiu, K.-Y., Atkins, M. B., Heath, E., Rojas-Uribe, G. A., Gonzalez Fernandez, M. E., Feyerabend, S., Pignata, S., Numakura, K., Cybulska Stopa, B., Zukov, R., Climent Duran, M. A., Maroto Rey, P. J., Montesa Pino, A., Chang, C.-H., Vengalil, S., Waddell, T. S., Cobb, P. W., Hauke, R., Anderson, D. M., Sarantopoulos, J., Gourdin, T., Zhang, T., Jayram, G., Fein, L. E., Harris, C., Beato, P. M. M., Flores, F., Estay, A., Rubiano, J. A., Bedke, J., Hauser, S., Neisius, A., Busch, J., Anai, S., Tsunemori, H., Sawka, D., Sikora-Kupis, B., Arranz, J. A., Delgado, I., Chen, C.-H., Gunderson, E., Tykodi, S., Koletsky, A., Chen, K., Agrawal, M., Kaen, D. L., Sade, J. P., Tatangelo, M. D., Parnis, F., Barbosa, F. M., Faucher, G., Iqbal, N., Marceau, D., Paradis, J.-B., Hanna, N., Acevedo, A., Ibanez, C., Villanueva, L., Galaz, P. P., Durango, I. C., Manneh, R., Kral, Z. , Holeckova, P., Hakkarainen, H., Ronkainen, H., Abadie-Lacourtoisie, S., Tartas, S., Goebell, P. J., Grimm, M.-O., Hoefner, T., Wirth, M., Panic, A., Schultze-Seemann, W., Yokomizo, A., Mizuno, R., Uemura, H., Eto, M., Tsujihata, M., Matsukawa, Y., Murakami, Y., Kim, M., Hamberg, P., Marczewska-Skrodzka, M., Szczylik, C., Humphreys, A. C., Jiang, P., Kumar, B., Lu, G., Desai, A., Karam, J. A., Keogh, G., Fleming, M., Zarba, J. J., Leiva, V. E., Mendez, G. A., Harris, S. J., Brown, S. J., Antonio Junior, J. N., Costamilan, R. D. C., Rocha, R. O., Muniz, D., Brust, L., Lalani, A.-K., Graham, J., Levesque, M., Orlandi, F., Kotasek, R., Deville, J. L., Borchiellini, D., Merseburger, A., Rink, M., Roos, F., McDermott, R., Oyama, M., Yamamoto, Y., Tomita, Y., Miura, Y., Ioritani, N., Westgeest, H., Kubiatowski, T., Bal, W., Girones Sarrio, R., Rowe, J., Prow, D. M., Senecal, F., Hashemi-Sadraei, N., Cole, S. W., Kendall, S. D., Richards, D. A., Schnadig, I. D., & Gupta, M.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 23
- Issue
- 9
- Pages
- 1133-1144
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4293708418
- Cited by
- 294
- References
- 18
- FWCI
- 35.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00487-9
- The paper
- Powles, T., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Gurney, H., Chang, Y.-H., Lee, J. L., Sarwar, N., Thiery-Vuillemin, A., Gross-Goupil, M., Mahave, M., Haas, N. B., Sawrycki, P., Burgents, J. E., Xu, L., Imai, K., . . . Gupta, M. (2022). Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00487-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.